BACKGROUND: As many as 40 % of breast cancer patients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic-venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009. METHODS: LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve. Follow-up was with pre- and postoperative lymphoscintigraphy, arm measurements, and (L-Dex®) bioimpedance spectroscopy. RESULTS: Over 26 months, 37 women underwent attempted LYMPHA, with successful completion in 27. Unsuccessful attempts were due to lack of a suitable vein (n = 3) and lymphatic (n = 5) or extensive axillary disease (n = 1). There were no LYMPHA-related complications. Mean follow-up time was 6 months (range 3-24 months). Among completed patients, 10 (37%) had a body mass index of ≥30 kg/m(2) (mean 27.9 ± 6.8 kg/m(2), range 17.4-47.6 kg/m(2)), and 17 (63%) received axillary radiotherapy. Excluding two patients with preoperative lymphedema and those with less than 3-month follow-up, the lymphedema rate was 3 (12.5%) of 24 in successfully completed and 4 (50 %) of 8 in unsuccessfully treated patients. CONCLUSIONS: Our transient lymphedema rate in this high-risk cohort of patients was 12.5%. Early data show that LYMPHA is feasible, safe, and effective for the primary prevention of breast cancer-related lymphedema.
BACKGROUND: As many as 40 % of breast cancerpatients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic-venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009. METHODS: LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve. Follow-up was with pre- and postoperative lymphoscintigraphy, arm measurements, and (L-Dex®) bioimpedance spectroscopy. RESULTS: Over 26 months, 37 women underwent attempted LYMPHA, with successful completion in 27. Unsuccessful attempts were due to lack of a suitable vein (n = 3) and lymphatic (n = 5) or extensive axillary disease (n = 1). There were no LYMPHA-related complications. Mean follow-up time was 6 months (range 3-24 months). Among completed patients, 10 (37%) had a body mass index of ≥30 kg/m(2) (mean 27.9 ± 6.8 kg/m(2), range 17.4-47.6 kg/m(2)), and 17 (63%) received axillary radiotherapy. Excluding two patients with preoperative lymphedema and those with less than 3-month follow-up, the lymphedema rate was 3 (12.5%) of 24 in successfully completed and 4 (50 %) of 8 in unsuccessfully treated patients. CONCLUSIONS: Our transient lymphedema rate in this high-risk cohort of patients was 12.5%. Early data show that LYMPHA is feasible, safe, and effective for the primary prevention of breast cancer-related lymphedema.
Authors: Nikita Gupta; Erik M Verhey; Ricardo A Torres-Guzman; Francisco R Avila; Antonio Jorge Forte; Alanna M Rebecca; Chad M Teven Journal: Plast Reconstr Surg Glob Open Date: 2021-08-25
Authors: Stanley G Rockson; John P Cooke; Ngan F Huang; Catarina Hadamitzky; Tatiana S Zaitseva; Magdalena Bazalova-Carter; Michael V Paukshto; Luqia Hou; Zachary Strassberg; James Ferguson; Yuka Matsuura; Rajesh Dash; Phillip C Yang; Shura Kretchetov; Peter M Vogt Journal: Biomaterials Date: 2016-06-07 Impact factor: 12.479
Authors: Kelly M Herremans; Morgan P Cribbin; Andrea N Riner; Dan W Neal; Tracy L Hollen; Pamela Clevenger; Derly Munoz; Shannon Blewett; Fantine Giap; Paul G Okunieff; Nancy P Mendenhall; Julie A Bradley; William M Mendenhall; Raymond B Mailhot-Vega; Eric Brooks; Karen C Daily; Coy D Heldermon; Julia K Marshall; Mariam W Hanna; Mark M Leyngold; Sarah S Virk; Christiana M Shaw; Lisa R Spiguel Journal: Ann Surg Oncol Date: 2021-08-07 Impact factor: 5.344
Authors: Angela Alexander; Terry Lynn Arnold; Sandra Bishnoi; Caroline Ballinger; Simona F Shaitelman; Mark V Schaverien; Lorenzo Cohen; Mary Dev; Naoto T Ueno Journal: J Cancer Date: 2018-04-06 Impact factor: 4.207
Authors: Summer E Hanson; Edward I Chang; Mark V Schaverien; Carrie Chu; Jesse C Selber; Matthew M Hanasono Journal: Plast Reconstr Surg Glob Open Date: 2020-03-27
Authors: Mark V Schaverien; Donald P Baumann; Jesse C Selber; Edward I Chang; Matthew M Hanasono; Carrie Chu; Summer E Hanson; Charles E Butler Journal: Plast Reconstr Surg Glob Open Date: 2020-03-20